Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
4 February 2016 Full-Year and Q4 2015 Results Financial Summary +---------------------+------+----+------++-----+----+------+ | |FY 2015 ||Q4 2015 ...
-
AstraZeneca PLC Full-Year and Q4 Results 2015 On Thursday, 4 February 2016, AstraZeneca PLC will release its full-year and Q4 2015 results at 07:00 GMT. A presentation will take place at 12:00...
-
TAGRISSO™ (osimertinib) approved in EU as first-in-class treatment for PATIENTS WITH EGFR T790M mutation-positive metastatic non-small cell lung cancer TAGRISSO™ is the first new medicine to be...
-
ASTRAZENECA COMPLETES TRANSACTION FOR MAJORITY EQUITY STAKE INVESTMENT IN ACERTA PHARMA AstraZeneca today announced that it has completed the transaction to acquire a majority equity stake in Acerta...
-
LYNPARZA™ (Olaparib) granted Breakthrough Therapy Designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer AstraZeneca today announced that...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 31 December 2015, Cori Bargmann, a Director of the Company notified us that, on 30 December 2015, she became...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 3 January 2016, Pascal Soriot, a Director of the Company, notified us that, on 31 December 2015, he ceased...
-
Result of the External Audit Tender AstraZeneca PLC (the Company) today announced a proposal to appoint PricewaterhouseCoopers LLP (PwC) as its external auditor for the financial year ending 31...
-
ZURAMPIC® (LESINURAD) APPROVED BY US FDA FOR PATIENTS WITH GOUT AstraZeneca (http://www.astrazeneca-us.com/) today announced that the US Food and Drug Administration (FDA) has approved...
-
TAGRISSO™ (osimertinib) RECEIVES positive chmp OPINION FOR patients with EGFR T790M mutation-positive METASTATIC non-small cell lung cancer CHMP positive recommendation is based on an objective...